secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protalix BioTherapeutics, Inc. (PLX)
CIK:        0001006281
Form:       8-K
Filed at:   2024-03-14T23:59:59+00:00
Accession:  0001558370-24-003160
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protalix reports 2023 net income $8.3M vs loss; Elfabrio approvals, $20M milestone
--------------------------------------------------------------------------------

- Revenue from goods $40.4M (+60% YoY); license/R&D services $25.1M (+13%).
- Net income $8.3M ($0.12 diluted EPS) vs net loss $14.9M in 2022.
- Cash $44.6M at year-end; Elfabrio approved in US, EU, UK, Switzerland, Israel.
- $20M milestone from Chiesi triggered by FDA approval; $17.5M Elfabrio sales post-approval.
- PRX-115 Phase I fully enrolled; results expected Q2 2024. New chairman appointed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006281/000155837024003160/0001558370-24-003160-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006281/000155837024003160/plx-20240314x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-003160

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer